Inhibiting DAAO via DAAO inhibitors can lead to increased synaptic D-serine levels and the regulation of NMDA receptor-evoked electrophysiological activity, thereby ameliorating NMDA receptor hypofunction and the cognitive deficits observed in schizophrenia. The gene discussed is DAO; the disease is schizophrenia.